Brendan Zangari1, Takemasa Tsuji2,3, Junko Matsuzaki2,3, Hemn Mohammadpour1, Cheryl Eppolito1, Sebastiano Battaglia1,4, Fumito Ito5, Thinle Chodon2,3, Richard Koya2,3, A J Robert McGray1, Kunle Odunsi6,7. 1. Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 2. University of Chicago Medicine Comprehensive Cancer Center, 5841 S Maryland Ave, Chicago, IL, 60637, USA. 3. Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, USA. 4. Department of Genetics and Genomics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 5. Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 6. University of Chicago Medicine Comprehensive Cancer Center, 5841 S Maryland Ave, Chicago, IL, 60637, USA. odunsia@bsd.uchicago.edu. 7. Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, USA. odunsia@bsd.uchicago.edu.
Abstract
BACKGROUND: T-cell longevity is undermined by antigen-driven differentiation programs that render cells prone to attrition through several mechanisms. CD8 + T cells that express the Tcf-1 transcription factor have undergone limited differentiation and exhibit stem-cell-like replenishment functions that facilitate persistence. We engineered human CD8 + T cells to constitutively express Tcf-1 and a TCR specific for the NY-ESO-1 cancer-associated antigen. Co-engineered cells were assessed for their potential for adoptive cellular immunotherapy. METHODS: Tcf-1 mRNA encoding TCF-1B and TCF-1E isoforms, along with GzmB expression were assessed in CD62L + CD57 -, CD62L - CD57 -, and CD62L - CD57 + CD8 + T cells derived from normal donor lymphocytes. The impact of stable Tcf-1B expression on CD8 + T-cell phenotype, anti-tumor activity, and cell-cycle activity was assessed in vitro and in an in vivo tumor xenograft model. RESULTS: TCF-1B and TCF-1E were dynamically regulated during self-renewal, with progeny of recently activated naïve T cells more enriched for TCF-1B mRNA. Constitutive TCF-1B expression improved the survival of TCR-engineered CD8 + T cells upon engagement with tumor cells. Tcf-1B prohibited the acquisition of a GzmB High state, and protected T cells from apoptosis associated with elicitation of effector function, and promoted stem cell-like characteristics. CONCLUSIONS: Tcf-1 protects TCR-engineered CD8 + T cells from activation induced cell death by restricting GzmB expression. Our study presents constitutive Tcf-1B expression as a potential means to impart therapeutic T cells with attributes of persistence for durable anti-tumor activity.
BACKGROUND: T-cell longevity is undermined by antigen-driven differentiation programs that render cells prone to attrition through several mechanisms. CD8 + T cells that express the Tcf-1 transcription factor have undergone limited differentiation and exhibit stem-cell-like replenishment functions that facilitate persistence. We engineered human CD8 + T cells to constitutively express Tcf-1 and a TCR specific for the NY-ESO-1 cancer-associated antigen. Co-engineered cells were assessed for their potential for adoptive cellular immunotherapy. METHODS: Tcf-1 mRNA encoding TCF-1B and TCF-1E isoforms, along with GzmB expression were assessed in CD62L + CD57 -, CD62L - CD57 -, and CD62L - CD57 + CD8 + T cells derived from normal donor lymphocytes. The impact of stable Tcf-1B expression on CD8 + T-cell phenotype, anti-tumor activity, and cell-cycle activity was assessed in vitro and in an in vivo tumor xenograft model. RESULTS: TCF-1B and TCF-1E were dynamically regulated during self-renewal, with progeny of recently activated naïve T cells more enriched for TCF-1B mRNA. Constitutive TCF-1B expression improved the survival of TCR-engineered CD8 + T cells upon engagement with tumor cells. Tcf-1B prohibited the acquisition of a GzmB High state, and protected T cells from apoptosis associated with elicitation of effector function, and promoted stem cell-like characteristics. CONCLUSIONS: Tcf-1 protects TCR-engineered CD8 + T cells from activation induced cell death by restricting GzmB expression. Our study presents constitutive Tcf-1B expression as a potential means to impart therapeutic T cells with attributes of persistence for durable anti-tumor activity.
Authors: Christian S Hinrichs; Zachary A Borman; Luca Gattinoni; Zhiya Yu; William R Burns; Jianping Huang; Christopher A Klebanoff; Laura A Johnson; Sid P Kerkar; Shicheng Yang; Pawel Muranski; Douglas C Palmer; Christopher D Scott; Richard A Morgan; Paul F Robbins; Steven A Rosenberg; Nicholas P Restifo Journal: Blood Date: 2010-10-22 Impact factor: 22.113
Authors: Luca Gattinoni; Christopher A Klebanoff; Douglas C Palmer; Claudia Wrzesinski; Keith Kerstann; Zhiya Yu; Steven E Finkelstein; Marc R Theoret; Steven A Rosenberg; Nicholas P Restifo Journal: J Clin Invest Date: 2005-06 Impact factor: 14.808
Authors: C H Bird; M E Christensen; M S J Mangan; M D Prakash; K A Sedelies; M J Smyth; I Harper; N J Waterhouse; P I Bird Journal: Cell Death Differ Date: 2014-01-31 Impact factor: 15.828
Authors: Bianca Heemskerk; Ke Liu; Mark E Dudley; Laura A Johnson; Andrew Kaiser; Stephanie Downey; Zhili Zheng; Thomas E Shelton; Kant Matsuda; Paul F Robbins; Richard A Morgan; Steven A Rosenberg Journal: Hum Gene Ther Date: 2008-05 Impact factor: 5.695
Authors: Jonathan T Sockolosky; Eleonora Trotta; Giulia Parisi; Lora Picton; Leon L Su; Alan C Le; Akanksha Chhabra; Stephanie L Silveria; Benson M George; Indigo C King; Matthew R Tiffany; Kevin Jude; Leah V Sibener; David Baker; Judith A Shizuru; Antoni Ribas; Jeffrey A Bluestone; K Christopher Garcia Journal: Science Date: 2018-03-02 Impact factor: 47.728
Authors: Andrew C Scott; Friederike Dündar; Paul Zumbo; Smita S Chandran; Christopher A Klebanoff; Mojdeh Shakiba; Prerak Trivedi; Laura Menocal; Heather Appleby; Steven Camara; Dmitriy Zamarin; Tyler Walther; Alexandra Snyder; Matthew R Femia; Elizabeth A Comen; Hannah Y Wen; Matthew D Hellmann; Niroshana Anandasabapathy; Yong Liu; Nasser K Altorki; Peter Lauer; Olivier Levy; Michael S Glickman; Jonathan Kaye; Doron Betel; Mary Philip; Andrea Schietinger Journal: Nature Date: 2019-06-17 Impact factor: 49.962
Authors: Giacomo Oliveira; Kari Stromhaug; Susan Klaeger; Tomasz Kula; Dennie T Frederick; Phuong M Le; Juliet Forman; Teddy Huang; Shuqiang Li; Wandi Zhang; Qikai Xu; Nicoletta Cieri; Karl R Clauser; Sachet A Shukla; Donna Neuberg; Sune Justesen; Gavin MacBeath; Steven A Carr; Edward F Fritsch; Nir Hacohen; Moshe Sade-Feldman; Kenneth J Livak; Genevieve M Boland; Patrick A Ott; Derin B Keskin; Catherine J Wu Journal: Nature Date: 2021-07-21 Impact factor: 69.504